Floatz logo

Paroxetine

Multiple Sclerosis

University of ManitobaSmall moleculePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB

View all 50 →

Same molecule, other indications

Paroxetine is also rated in:

depressive disorderDormant
BBB
Indicative ·
76 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →